retatrutide weight loss retatrutide clinical trial Results:Trial Data and FDA Status Retatrutide: A Triple Agonist Shaping

Vivek Bansal, MD MPH, Triple Board-Certified Endocrinologist and Founder of The EnLyv Clinics in Bridgewater, NJ

'Glucagon-like peptide 1 receptor agonists in the treatment of type 2 diabetesstate-of-the-art.' Molecular Metabolism

Despite the improvement in GH/IGF-1 levels (GH 10.6 ng/mL, IGF-1 462 ng/mL), her glycemic control drastically deteriorated for 4 months (Hb1Ac 8.212.0%)

While generally mild and infrequently leading to discontinuation, this finding is being closely monitored in subsequent TRIUMPH readouts

GLP-1 medications may increase skin reactivity slightly, especially in patients who experience the skin barrier impairment that some research has documented